GeneseeqPrime™HRD
Comprehensively evaluates homologous recombination deficiency
GeneseeqPrime™HRD is a next-generation sequencing-based laboratory developed test that analyzes homologous recombination deficiency (HRD)-related genomic instabilities through a genome-wide analysis approach. It also detects genomic alterations in 437 cancer-relevant genes, including BRCA1/2 and other homologous recombination repair (HRR)-relevant genes.
WHO IS IT FOR
Patients with solid tumors seeking precision medicine, including PARP inhibitor selection, other targeted therapy options and immunotherapies
SAMPLE TYPE
Tumor tissue (FFPE block/slides, or frozen tissue)
All-in-one test
Genome-wide HRD score by assessing loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST)
Genomic alterations in 437 cancer-relevant genes, including 26 HRR genes
Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR)
Assesses other key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes
GeneseeqPrime™HRD Report
Evaluates HRD score and HRR-gene alterations to inform PARP inhibitor selection
Assesses TMB, MSI and dMMR with the option to add the PD-L1 immunohistochemistry (IHC) test to better inform immunotherapy decisions
Provides information on clinically actionable genomic alterations and their associated targeted therapy, both approved drugs and those in clinical trials
Reveals potential resistance mechanisms to current therapies and options for alternative treatments
Assesses genetic predisposition to certain cancer types for early intervention
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
